COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 2 for:    LY-CoV555
Previous Study | Return to List | Next Study

A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04411628
Recruitment Status : Recruiting
First Posted : June 2, 2020
Last Update Posted : July 3, 2020
AbCellera Biologics Inc.
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection into a vein to participants hospitalized with COVID-19. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate it. Participation could last about 8 weeks and may include up to 15 visits in the hospital or the home.

Condition or disease Intervention/treatment Phase
COVID-19 Drug: LY3819253 Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending Dose, Phase 1 First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19
Actual Study Start Date : May 28, 2020
Estimated Primary Completion Date : August 23, 2020
Estimated Study Completion Date : August 23, 2020

Arm Intervention/treatment
Experimental: LY3819253
LY3819253 administered intravenously (IV).
Drug: LY3819253
Administered IV.
Other Name: LY-CoV555

Placebo Comparator: Placebo
Placebo administered IV.
Drug: Placebo
Administered IV.

Primary Outcome Measures :
  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline through Day 60 ]
    A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

Secondary Outcome Measures :
  1. Pharmacokinetics (PK): Area Under the Concentration-time Curve (AUC) of LY3819253 [ Time Frame: Baseline through Day 29 ]
    PK: AUC of LY3819253

  2. Pharmacodynamics (PD): Change from Baseline to Day 29 in Viral Load [ Time Frame: Baseline, Day 29 ]
    PD: Change from Baseline in Viral Load

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Are hospitalized or in the process of being admitted to hospital and have an initial laboratory determination of current COVID-19 infection less than or equal to (≤)72 hours prior to randomization
  • Are men or non-pregnant women
  • Women of childbearing potential must agree to use at least one highly effective form of contraception for the entirety of the study
  • Agree to the collection of nasopharyngeal swabs and venous blood

Exclusion Criteria:

  • Require mechanical ventilation or anticipated impending need for mechanical ventilation
  • Received convalescent COVID-19 plasma treatment prior to enrollment
  • Were resident in a nursing home or long-term care facility immediately prior to current hospitalization
  • Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking investigational product
  • Have an oxygen saturation (SpO2) less than (<)88 percent (%) while breathing room air at rest at randomization.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04411628

Layout table for location contacts
Contact: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559

Layout table for location information
United States, California
Cedars Sinai Medical Center Recruiting
Los Angeles, California, United States, 90048
Contact    424-315-2861      
Principal Investigator: Peter Chen         
Veterans Affairs Medical Center San Diego Not yet recruiting
San Diego, California, United States, 92161
Contact    480-256-6444      
Principal Investigator: Mary K Lewinski         
United States, Georgia
Emory University Recruiting
Atlanta, Georgia, United States, 30322
Contact    404-712-1435      
Principal Investigator: Nadine G Rouphael         
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact    617-726-6609      
Principal Investigator: Michael L Dougan         
University of Massachusetts Medical Center Not yet recruiting
Worcester, Massachusetts, United States, 01655
Contact    505-856-0056      
Principal Investigator: ROBERT FINBERG         
United States, Michigan
University of Michigan Recruiting
Ann Arbor, Michigan, United States, 48109
Contact    734-936-3662      
Principal Investigator: Pauline K Park         
United States, Nebraska
Quality Clinical Research, Inc. Recruiting
Omaha, Nebraska, United States, 68114
Contact    402-934-0044      
Principal Investigator: Rudolph J Kotula         
United States, New York
Alexandria Center for Life - NYC/ NYCEDC Recruiting
New York, New York, United States, 10016
Contact    646-501-0681      
Principal Investigator: Mark J Mulligan         
United States, North Carolina
University of North Carolina Recruiting
Chapel Hill, North Carolina, United States, 27514
Contact    410-908-7779      
Principal Investigator: William A Fischer         
Unified Research Enterprise Brody School of Medicine at ECU Not yet recruiting
Greenville, North Carolina, United States, 27834
Contact    252-744-0860      
Principal Investigator: Paul P Cook         
United States, Pennsylvania
Temple Univ School of Med Recruiting
Philadelphia, Pennsylvania, United States, 19140
Contact    215-707-1503      
Principal Investigator: GERARD J CRINER         
Sponsors and Collaborators
Eli Lilly and Company
AbCellera Biologics Inc.
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Additional Information:
Layout table for additonal information
Responsible Party: Eli Lilly and Company Identifier: NCT04411628    
Other Study ID Numbers: 17823
J2W-MC-PYAA ( Other Identifier: Eli Lilly and Company )
First Posted: June 2, 2020    Key Record Dates
Last Update Posted: July 3, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes